OCEA חוב כולל להון Ocean Biomedical Corp

Ocean Biomedical, Inc. (OCEA) focuses its biotechnological capabilities on developing therapies for oncology and fibrosis, a trend reflected in the clearly visualized share price dynamics, where the indicator stands at 0.00. The business relies on external investment due to a lack of profitability and the inherent risks of cancer drug trial failures. Meanwhile, the company implements strict temperature controls during the transportation of its experimental samples to preserve their properties.

This ratio compares total liabilities to equity, determining the business's reliance on debt financing and the associated debt service risks. For Ocean Biomedical, Inc. (OCEA), which generates no revenue and competes solely for research investments, the current total debt-to-equity level serves as an indicator of financial stability in the absence of operational cash flow.